WO2010057811A2 - Utilisation de la canthaxanthine et/ou de 25-oh d3 pour améliorer l’éclosivité chez des volailles - Google Patents

Utilisation de la canthaxanthine et/ou de 25-oh d3 pour améliorer l’éclosivité chez des volailles Download PDF

Info

Publication number
WO2010057811A2
WO2010057811A2 PCT/EP2009/064963 EP2009064963W WO2010057811A2 WO 2010057811 A2 WO2010057811 A2 WO 2010057811A2 EP 2009064963 W EP2009064963 W EP 2009064963W WO 2010057811 A2 WO2010057811 A2 WO 2010057811A2
Authority
WO
WIPO (PCT)
Prior art keywords
canthaxanthin
vitamin
poultry
hatchability
ppm
Prior art date
Application number
PCT/EP2009/064963
Other languages
English (en)
Other versions
WO2010057811A3 (fr
Inventor
Jose-Maria Hernandez
Gilbert Weber
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41562097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010057811(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL09748799T priority Critical patent/PL2358214T3/pl
Priority to US13/128,275 priority patent/US20110224306A1/en
Priority to ES09748799.5T priority patent/ES2439712T3/es
Priority to EP09748799.5A priority patent/EP2358214B1/fr
Priority to SG2011016557A priority patent/SG169565A1/en
Priority to AU2009317402A priority patent/AU2009317402B2/en
Priority to JP2011535997A priority patent/JP2012509253A/ja
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to CN2009801462363A priority patent/CN102215700A/zh
Priority to MX2011005239A priority patent/MX2011005239A/es
Priority to RU2011124942/15A priority patent/RU2498613C2/ru
Priority to CA2737680A priority patent/CA2737680C/fr
Priority to BRPI0913531-6A priority patent/BRPI0913531B1/pt
Publication of WO2010057811A2 publication Critical patent/WO2010057811A2/fr
Priority to PH12011500511A priority patent/PH12011500511B1/en
Publication of WO2010057811A3 publication Critical patent/WO2010057811A3/fr
Priority to US14/034,384 priority patent/US20140024626A1/en
Priority to US15/413,254 priority patent/US20170128466A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the present invention relates to the use of canthaxanthin and/or at least one vitamin D metabolite, preferably 25-hydroxy vitamin D3 (25-OH D3), for improving breeder hatchability. More particularly the invention relates to the use of canthaxanthin and/or 25-hydroxy vitamin D3 in the manufacture of a feed or veterinary composition for improving hatchability in poultry.
  • Applicant now surprisingly found that relatively high concentrations of essential nutrients in the embryo such as canthaxanthin or 25-OH-D3 supplied via maternal supplementation are related to improved hatchability, fertility and lower embryo mortality during the first phase of embryo development.
  • Tritsch et al. disclose a feed premix composition of at least 25-OH D3 in an amount between 5% and 50% (wt/wt) dissolved in oil and an antioxidant, an agent encapsulating droplets of 25-OH D3 and oil, and a nutritional additive (e.g., Vitamin D3).
  • the premix may be added to poultry, swine, canine, or feline food. This composition stabilizes 25- OH D3 against oxidation.
  • Simoes-Nunes et al. discloses adding a combination of 25-OH Vitamin D3 and Vitamin D3 to animal feed. In particular, about 10 ⁇ g/kg to about 100 ⁇ g/kg of 25-OH Vitamin D3 and about 200 IU/kg to about 4,000 IU/kg of Vitamin D3 are added to swine feed. This addition improves the pig's bone strength.
  • Stark et al. disclose adding a combination of 25-OH Vitamin D3 and Vitamin D3 to poultry feed to ameliorate the effects of tibial dyschondroplasia.
  • Borenstein et al US 5,043,170 discloses the combination of Vitamin D3 and either 1 -alpha- hydroxycholecalciferol or 1 alpha, 25-dihydroxycholecalciferol to improve egg strength and leg strength in laying hens and older hens.
  • Fleshner-Barak discloses administration of bisphosphonate compound and natural vitamin D derivative such as 1 ,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3, or 25-OH vitamin D3.
  • Daifotis et al. disclose inhibiting bone resorption by a combination of at least one bisphosphonate compound and from about 100 IU to about 60,000 IU of a no activated metabolite of vitamin D2 and/or vitamin D3.
  • Vitamin D metabolite means any metabolite of Vitamin D as for example 25-hydroxy vitamin D3, 1 ,25-dihydroxy vitamin D3 or 24,25-dihydroxy vitamin D3.
  • 25-OH D3 refers specifically to 25-hydroxy vitamin D3.
  • Pesttry is meant to include turkeys, ducks and chickens (including but not limited to broiler chicks, layers, breeders).
  • Canthaxanthin and 25-OH D3 may be obtained from any source, and a composition thereof may be prepared using convenient technology.
  • one or more feed compositions suitable for poultry use are provided to administer canthaxanthin or 25-OH D3 and combinations thereof as nutrients to improve hatchability, fertility and lower embryo mortality during the first phase of embryo development.
  • a poultry feed which comprises from about 10 ⁇ g/kg to about 100 ⁇ g/kg of 25-OH D3 and/or from about 2 to 100 ppm canthaxanthin, preferably 2 to 10 ppm.
  • a method of administering canthaxanthin and/or 25-OH D3 to poultry breeders is provided to improve hatchability, fertility and lower embryo mortality during the first phase of embryo development.
  • the method for improving hatchability in poultry comprises administering to the animal in need of such treatment an amount of about 2 ppm to 100 ppm of canthaxanthin, preferably 2 to 10 ppm, and/or about 10 ⁇ g/kg to about 100 ⁇ g/kg of 25-OH D3.
  • a premix composition for poultry feed comprising 25-hydroxy vitamin D3 and canthaxanthin is provided.
  • Canthaxanthin and 25-hydroxy vitamin D3 are suitably administered together with the food.
  • the term food as used herein comprises both solid and liquid food as well as drinking fluids such as drinking water.
  • inventive ingredients can be added as a formulated powder to a premix containing other minerals, vitamins, amino acids and trace elements which is added to regular animal food and thorough mixing to achieve even distribution therein.
  • a food premix may be prepared on the basis of regular food components by adding these active ingredients to such food components in higher concentration.
  • canthaxanthin compound is available under the Trademark ROVIM IX® Hy-D® 1.25 % and canthaxanthin under the Trademark CAROPHYLL ⁇ Red.
  • the composition also contains one or more of the following ingredients: Vitamin A, Vitamin E, Biotin, copper (e.g. as CuSO 4 ), zinc (e.g. as ZnSO 4 ), cobalt (e.g. as CoSO 4 ), selenium (e.g. as Na 2 SeO 3 ), iodine (e.g. as Kl), manganese (e.g. as MnSO 4 ) and/or calcium (e.g. as CaSO 4 ).
  • Vitamin A Vitamin E
  • Biotin copper
  • copper e.g. as CuSO 4
  • zinc e.g. as ZnSO 4
  • cobalt e.g. as CoSO 4
  • selenium e.g. as Na 2 SeO 3
  • iodine e.g. as Kl
  • manganese e.g. as MnSO 4
  • calcium e.g. as CaSO 4
  • Example 1 Effect of Carophyll Red (Canthaxanthin) on the productive and reproductive development of broiler chickens
  • the birds underwent the recommended handling and feeding practices in the breeders' guide.
  • To assess the fertility of the birds in each box an incubation session was carried out for one week, and using embryo diagnostics on the eggs that did not hatch, the percentage of fertility in each box was determined. The level of fertility was taken into consideration when distributing the treatments to each of the boxes, so that all treatments had the same level of fertility at the beginning of the study.
  • the diet given to the birds was a standard feed for broiler chickens with the addition of the products that were tested.
  • the feed met all nutritional requirements in relation to the developmental stage of the birds and the recommendations in the breeders' guide.
  • the feed was entirely vegetable-based, using corn and Soya bran (Appendices 1 , 2 and 3).
  • the experimental design was entirely random, with two treatments and six groups of 30 female and 3 male chickens.
  • the laying rate was calculated weekly. To assess the weight of the eggs, specific gravity, average weight of eggs, yolk weight, albumen weight and the coloration of the yolk, all the eggs that were not considered suitable for incubation, collected on any given day, were used. Specific gravity was determined through the emersion of the eggs in saline solutions with densities of 1065; 1070; 1075; 1080; 1085; 1090 and 1095. The weighing of the eggs, yolks and albumen were carried out using a precision weighing scale (0.001 g). The coloration of the yolks was determined using the color fan from DSM Nutritional Products ® .
  • the eggs were collected daily. They were then classified and marked with the number of the corresponding box. Those that were not considered suitable for incubation were stored for a maximum period of seven days in an air-conditioned room with temperature and humidity control. Incubation was carried out in a multi-stage incubator and on day 18, the eggs were transferred to a brooder. On day 21 the chicks were taken out of the brooder, vaccinated and classified. The eggs that did not hatch then underwent embryo diagnostics to evaluate fertility and the phase of embryonic mortality.
  • Example 2 The test has been executed according to Example 1 , with the addition of ROVIMIX® Hy-D®.
  • the treatments in example 2 were as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l’utilisation de canthaxanthine et/ou de 25-hydroxy-vitamine D3 (25-OH D3) pour améliorer l’éclosivité et la fertilité de reproducteurs et pour diminuer la mortalité des embryons chez des volailles. Plus particulièrement, l’invention concerne l’utilisation de canthaxanthine et/ou de 25-hydroxy-canthaxanthine dans la fabrication d’une composition alimentaire ou vétérinaire pour améliorer l’éclosivité chez des volailles.
PCT/EP2009/064963 2008-11-19 2009-11-11 Utilisation de la canthaxanthine et/ou de 25-oh d3 pour améliorer l’éclosivité chez des volailles WO2010057811A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN2009801462363A CN102215700A (zh) 2008-11-19 2009-11-11 角黄素和/或25-oh d3用于家禽中改进的孵化率的用途
MX2011005239A MX2011005239A (es) 2008-11-19 2009-11-11 Uso de cantaxantina y/o 25-oh d3 para mejorar la capacidad de eclosion en aves.
US13/128,275 US20110224306A1 (en) 2008-11-19 2009-11-11 Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry
RU2011124942/15A RU2498613C2 (ru) 2008-11-19 2009-11-11 Применение кантаксантина и/или 25-он-d3 для улучшения выводимости домашней птицы
SG2011016557A SG169565A1 (fr) 2008-11-19 2009-11-11
AU2009317402A AU2009317402B2 (en) 2008-11-19 2009-11-11 Use of Canthaxanthin and/or 25-OH D3 for improved hatchability in poultry
JP2011535997A JP2012509253A (ja) 2008-11-19 2009-11-11 家禽における孵化率向上のためのカンタキサンチン及び／又は２５−ｏｈｄ３の使用
PL09748799T PL2358214T3 (pl) 2008-11-19 2009-11-11 Zastosowanie kantaksantyny i/lub 25-OH D3 dla poprawy wylęgowości u drobiu
BRPI0913531-6A BRPI0913531B1 (pt) 2008-11-19 2009-11-11 uso de cantaxantina e 25-oh d3 para melhorar a eclodibilidade de aves domésticas
ES09748799.5T ES2439712T3 (es) 2008-11-19 2009-11-11 Uso de cantaxantina y/o 25-OH D3 para una capacidad de eclosión mejorada en aves de corral
EP09748799.5A EP2358214B1 (fr) 2008-11-19 2009-11-11 Utilisation de la canthaxanthin et/ou du 25-oh d3 pour l'amelioration de l'eclosion chez la volaille
CA2737680A CA2737680C (fr) 2008-11-19 2009-11-11 Utilisation de la canthaxanthine et/ou de 25-oh d3 pour ameliorer l'eclosivite chez des volailles
PH12011500511A PH12011500511B1 (fr) 2008-11-19 2011-03-11
US14/034,384 US20140024626A1 (en) 2008-11-19 2013-09-23 Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry
US15/413,254 US20170128466A1 (en) 2008-11-19 2017-01-23 Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08020153.6 2008-11-19
EP08020153 2008-11-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/128,275 A-371-Of-International US20110224306A1 (en) 2008-11-19 2009-11-11 Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry
US14/034,384 Division US20140024626A1 (en) 2008-11-19 2013-09-23 Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry

Publications (2)

Publication Number Publication Date
WO2010057811A2 true WO2010057811A2 (fr) 2010-05-27
WO2010057811A3 WO2010057811A3 (fr) 2011-03-17

Family

ID=41562097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/064963 WO2010057811A2 (fr) 2008-11-19 2009-11-11 Utilisation de la canthaxanthine et/ou de 25-oh d3 pour améliorer l’éclosivité chez des volailles

Country Status (15)

Country Link
US (3) US20110224306A1 (fr)
EP (1) EP2358214B1 (fr)
JP (1) JP2012509253A (fr)
KR (1) KR20110095270A (fr)
CN (2) CN104585500A (fr)
AU (1) AU2009317402B2 (fr)
BR (1) BRPI0913531B1 (fr)
CA (1) CA2737680C (fr)
ES (1) ES2439712T3 (fr)
MX (1) MX2011005239A (fr)
PH (1) PH12011500511B1 (fr)
PL (1) PL2358214T3 (fr)
RU (1) RU2498613C2 (fr)
SG (1) SG169565A1 (fr)
WO (1) WO2010057811A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015651A1 (fr) * 2009-08-07 2011-02-10 Dsm Ip Assets B.V. Utilisation de composés de canthaxanthine
WO2011076557A1 (fr) * 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Utilisation de canthaxanthine et/ou de 25-hydroxy vitamine d3 (25-oh d3) pour la reproductivité et la performance améliorées des coqs
WO2014102643A1 (fr) * 2012-12-27 2014-07-03 Dsm Ip Assets B.V. Nouvelle utilisation de la cantaxanthine et de la 25-hydroxy-vitamine d3
WO2015184311A3 (fr) * 2014-05-30 2016-01-21 Cargill, Incorporated Procédé d'alimentation d'un animal
WO2016113382A1 (fr) 2015-01-15 2016-07-21 Dsm Ip Assets B.V. Combinaison de 25-hydroxyvitamine d et d'antioxydants/anti-inflammatoires pour la santé ovarienne des volailles
WO2016113387A1 (fr) * 2015-01-15 2016-07-21 Dsm Ip Assets B.V. Combinaison de 25-hydroxyvitamine d et d'antioxydants/anti-inflammatoires pour produits nutraceutiques destinés à l'usage humain
KR20210117352A (ko) * 2013-06-18 2021-09-28 디에스엠 아이피 어셋츠 비.브이. 칸타잔틴의 신규한 용도

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003063A1 (fr) * 2013-05-31 2016-04-13 DSM IP Assets B.V. Complément alimentaire et son utilisation
CN105211579A (zh) * 2015-11-05 2016-01-06 江苏京海禽业集团有限公司 一种大体型种母鸡产蛋期饲料

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043170A (en) 1989-02-14 1991-08-27 Hoffmann-La Roche Inc. Animal feed composition containing a vitamin D metabolite
US5695794A (en) 1995-08-10 1997-12-09 Amoco Corporation Use of 25-hydroxycholecalciferol in a dietary supplement process for ameliorating the effects of tibial dyschondroplasia in poultry while maintaining weight gain
WO2003007916A1 (fr) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Formes posologiques pour la liberation gastrique immediate d'un stimulateur de transport du calcium et la liberation gastrique retardee d'un bis-phosphonate
US20030170324A1 (en) 2002-01-15 2003-09-11 Jean-Claude Tritsch 25-Hydroxy Vitamin D3 compositions
WO2003086415A1 (fr) 2002-04-05 2003-10-23 Merck & Co., Inc. Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
US20050064018A1 (en) 2003-09-22 2005-03-24 Carlos Simoes-Nunes Use of vitamin D compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3727735A1 (de) * 1987-08-20 1989-03-02 Henkel Kgaa Geschmacksverbesserung von huehnereiern
US4970203A (en) * 1988-12-09 1990-11-13 Deluca Hector F Method for improving reproductive functions in mammals
DE59306812D1 (de) * 1992-04-14 1997-07-31 Hoffmann La Roche Präparate von fettlöslichen Substanzen
WO2001058277A1 (fr) * 2000-02-07 2001-08-16 Rhone-Poulenc Animal Nutrition Procede d'amelioration des conditions d'elevage de jeune volaille

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043170A (en) 1989-02-14 1991-08-27 Hoffmann-La Roche Inc. Animal feed composition containing a vitamin D metabolite
US5695794A (en) 1995-08-10 1997-12-09 Amoco Corporation Use of 25-hydroxycholecalciferol in a dietary supplement process for ameliorating the effects of tibial dyschondroplasia in poultry while maintaining weight gain
WO2003007916A1 (fr) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Formes posologiques pour la liberation gastrique immediate d'un stimulateur de transport du calcium et la liberation gastrique retardee d'un bis-phosphonate
US20030170324A1 (en) 2002-01-15 2003-09-11 Jean-Claude Tritsch 25-Hydroxy Vitamin D3 compositions
WO2003086415A1 (fr) 2002-04-05 2003-10-23 Merck & Co., Inc. Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
US20050064018A1 (en) 2003-09-22 2005-03-24 Carlos Simoes-Nunes Use of vitamin D compounds

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015651A1 (fr) * 2009-08-07 2011-02-10 Dsm Ip Assets B.V. Utilisation de composés de canthaxanthine
WO2011076557A1 (fr) * 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Utilisation de canthaxanthine et/ou de 25-hydroxy vitamine d3 (25-oh d3) pour la reproductivité et la performance améliorées des coqs
WO2014102643A1 (fr) * 2012-12-27 2014-07-03 Dsm Ip Assets B.V. Nouvelle utilisation de la cantaxanthine et de la 25-hydroxy-vitamine d3
KR102411513B1 (ko) 2013-06-18 2022-06-22 디에스엠 아이피 어셋츠 비.브이. 칸타잔틴의 신규한 용도
KR20210117352A (ko) * 2013-06-18 2021-09-28 디에스엠 아이피 어셋츠 비.브이. 칸타잔틴의 신규한 용도
RU2721269C2 (ru) * 2014-05-30 2020-05-18 Карджилл, Инкорпорейтед Способ кормления животного
WO2015184311A3 (fr) * 2014-05-30 2016-01-21 Cargill, Incorporated Procédé d'alimentation d'un animal
US10729159B2 (en) 2014-05-30 2020-08-04 Cargill, Incorporated Method of feeding an animal
WO2016113387A1 (fr) * 2015-01-15 2016-07-21 Dsm Ip Assets B.V. Combinaison de 25-hydroxyvitamine d et d'antioxydants/anti-inflammatoires pour produits nutraceutiques destinés à l'usage humain
US20180000124A1 (en) * 2015-01-15 2018-01-04 Dsm Ip Assets B.V. Poultry feed with combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories
JP2018503628A (ja) * 2015-01-15 2018-02-08 ディーエスエム アイピー アセッツ ビー．ブイ． ウシの健康のための、２５−ヒドロキシビタミンｄおよび抗酸化剤／抗炎症剤の組合せ
JP2018504106A (ja) * 2015-01-15 2018-02-15 ディーエスエム アイピー アセッツ ビー．ブイ． ２５−ヒドロキシビタミンｄと酸化防止剤／抗炎症剤との組み合わせを含む家禽飼料
JP2018506962A (ja) * 2015-01-15 2018-03-15 ディーエスエム アイピー アセッツ ビー．ブイ． 家禽の卵巣の健康のための２５−ヒドロキシビタミンｄと酸化防止剤／抗炎症剤との組み合わせ
US20180271118A1 (en) * 2015-01-15 2018-09-27 Dsm Ip Assets B.V. Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health
US10517316B2 (en) 2015-01-15 2019-12-31 Dsm Ip Assets B.V. Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for bovine health
JP2018503372A (ja) * 2015-01-15 2018-02-08 ディーエスエム アイピー アセッツ ビー．ブイ． 家禽における肥満及び心血管障害を予防する方法
US10668088B2 (en) 2015-01-15 2020-06-02 Dsm Ip Assets B.V. Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for human nutraceuticals
CN107105744A (zh) * 2015-01-15 2017-08-29 帝斯曼知识产权资产管理有限公司 用于人营养品的25‑羟基维生素d与抗氧化剂/抗炎剂的组合
US10863756B2 (en) 2015-01-15 2020-12-15 Dsm Ip Assets B.V. Method of preventing obesity and cardiovascular problems in poultry
US11040045B2 (en) 2015-01-15 2021-06-22 Dsm Ip Assets B.V. Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for human nutraceuticals
CN107105712A (zh) * 2015-01-15 2017-08-29 帝斯曼知识产权资产管理有限公司 预防家禽肥胖和心血管问题的方法
WO2016113382A1 (fr) 2015-01-15 2016-07-21 Dsm Ip Assets B.V. Combinaison de 25-hydroxyvitamine d et d'antioxydants/anti-inflammatoires pour la santé ovarienne des volailles

Also Published As

Publication number Publication date
RU2011124942A (ru) 2012-12-27
AU2009317402B2 (en) 2013-10-17
PH12011500511B1 (fr) 2013-12-10
SG169565A1 (fr) 2011-04-29
KR20110095270A (ko) 2011-08-24
ES2439712T3 (es) 2014-01-24
CA2737680C (fr) 2018-01-02
AU2009317402A1 (en) 2010-05-27
CN102215700A (zh) 2011-10-12
CA2737680A1 (fr) 2010-05-27
US20140024626A1 (en) 2014-01-23
MX305874B (fr) 2012-12-04
BRPI0913531B1 (pt) 2021-02-23
RU2498613C2 (ru) 2013-11-20
MX2011005239A (es) 2011-06-17
EP2358214B1 (fr) 2013-10-02
US20110224306A1 (en) 2011-09-15
JP2012509253A (ja) 2012-04-19
US20170128466A1 (en) 2017-05-11
BRPI0913531A2 (pt) 2019-08-27
PL2358214T3 (pl) 2014-03-31
EP2358214A2 (fr) 2011-08-24
CN104585500A (zh) 2015-05-06
WO2010057811A3 (fr) 2011-03-17

Similar Documents

Publication Publication Date Title
AU2009317402B2 (en) Use of Canthaxanthin and/or 25-OH D3 for improved hatchability in poultry
Naghshi et al. Investigation the effect of different levels of Azolla (Azolla pinnata) on performance and carcass characteristics of cobb broiler chicks
Sahr et al. Effects of in ovo injection of inorganic salts of Zn, Cu and Mn on hatching traits and post-hatch performance of broiler chickens in the tropics
Silva Effects of dietary 25-hydroxycholecalciferol on growth, production performance, eggshell quality and bone traits of brown egg layers housed under commercial conditions
US20170156370A1 (en) Novel use of canthaxanthin and 25-hydroxy vitamin d3
US9596878B2 (en) Use of canthaxanthin
RU2159558C1 (ru) Способ кормления животных и птицы
Hammod et al. The effect of partial replacement of maize by date pits on broiler performance
US20160143921A1 (en) Use of canthaxanthin and/or 25-oh d3 for improved reproductivity and performance of roosters
WO2011015651A1 (fr) Utilisation de composés de canthaxanthine
Mahrose et al. Response of laying hens to dietary vitamins A, E and selenium supplementation during summer months
Coto et al. Effect of source and level of maternal vitamin D on carryover to newly hatched chicks
Gharib et al. Effect of the number of incubated eggs and nurturing squabs on the behaviour and performance of breeding pigeons
Wahyuni et al. Egg's vitamin E deposition of Kedu breeder chicken fed improved diets.
Dawod et al. Effect of Adding Different Levels of Vitamin D3 to Diet and its Relationship to Qualitative Traits and Hatchability for Japanese Quail
JP2020158488A (ja) 産卵雌鶏に対するカンタキサンチンの使用
Mehrdad et al. THE EFFECT OF SUPRAPHYSIOLOGICAL DOSES OF VITAMIN E ON PERFORMANCE OF BROILER BREEDERS FLOCK
Hagan et al. Response of two different broiler genotypes to diets containing cocoa pod husk.
Mkhize Investigating the high incidence of bone disorders in a broiler farm: a case study
Ali et al. Archives of Agriculture Research and Technology (AART)
CZ2006762A3 (cs) Zpusob zvýšení obsahu vitamínu E a A v živocišných produktech

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980146236.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09748799

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009748799

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011535997

Country of ref document: JP

Ref document number: 1861/DELNP/2011

Country of ref document: IN

Ref document number: 12011500511

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2737680

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009317402

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009317402

Country of ref document: AU

Date of ref document: 20091111

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13128275

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20117011293

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/005239

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011124942

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0913531

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110303